Synexus(R) Achieves Record With More Than 10,000 Patients Enrolled In Clinical Studies

Main Category: Clinical Trials / Drug Trials
Article Date: 28 Apr 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Synexus® has achieved a new record for an organisation, which recruits and runs clinical trials, with more than 10,000 patients currently enrolled in late stage clinical trials at 14 hub sites in six countries.

Synexus® has found that its hub site model is increasingly being taken up by the pharma industry as it dramatically reduces costs - often by a factor of 10 - increases the quality of the data and speeds up recruitment.

More than 25 clinical trials are presently being carried out at hub sites in the UK, Poland, Hungary, Bulgaria, India and South Africa, into a wide variety of therapeutic areas including osteoporosis, hypertension, cancer prevention, diabetes, sexual dysfunction, cardiac disease, urinary incontinence, migraine and osteoarthritis.

Michael Fort CEO of Synexus® commented, "We are really pleased to have achieved this milestone of 10,000 patients. We are hoping by next year we will have doubled this number as we increase the capacity of our existing hub sites and open new sites in the US and Eastern Europe. This expansion is being driven from industry which wants to reduce costs and professionalise the recruitment and running of late stage clinical trials."

Synexus® background

Synexus® which is headquartered in Chorley, Manchester, England, is the world's largest multi-national company dedicated to the recruitment and running of late stage clinical trials.

Synexus® recruits participants for clinical trials on behalf of pharmaceutical, biotech and CROs. The clinical trials are then run and managed by Synexus® at 14 hub sites across the UK, Poland, Hungary, Bulgaria, India and South Africa.

Synexus® is presently working with more than thirty different pharma companies on new studies including Pfizer, Merck, Novartis, AZ, GSK, Amgen, BI, Solvay, Daiichi-Sankyo, Astellas, Shire, Reckitt Benckiser, Servier and Abbott as well as with the major CROs Quintiles, PPD, Covance, Kendle and ICON.

Synexus® pioneered the running of clinical trials at hub sites as against the traditional method of contracting with primary care physicians, who on average only recruit and manage five patients each.

Synexus